Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Plby Group Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Plby Group Inc trades at $0.97 (market cap $122.20M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 8× Plby Group Inc's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Plby Group Inc for 24 Days on average.
| MRVI | PLBY | |
|---|---|---|
Market Cap | $972.90M | $122.20M |
Volume | 4,325,710 | 540,321 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $2.71 |
52-Week Low | $2.83 | $0.98 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $1.08B | $267.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
PLBY trades at $0.99, down 0.32% with a bearish technical signal. The company shows improving fundamentals with revenue stabilizing around $121M in 2025 and narrowing losses from -$278M in 2022 to -$13M. Recent Q2 2026 earnings beat expectations with positive operating cash flow. Analyst sentiment remains strong with 75% buy ratings, while technical indicators show oversold conditions with RSI at neutral levels.
The outlook suggests cautious optimism as PLBY demonstrates operational improvement and debt reduction, though negative shareholder equity and high P/E ratio of 51 present valuation concerns. Key risks include persistent negative equity and competitive pressures in the consumer discretionary space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
